MedinCell S.A. (ENXTPA: MEDCL)
Health Care · Pharmaceuticals · FR
€24.86
+11.98% today · -16.5% 1Y
MedinCell S.A. (ENXTPA: MEDCL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $897.28M and employs 141 people.
Over the last twelve months the share price has lost 16.5%, trading between 19.69 and 39.68.
Tweenvest scores MedinCell S.A. across four factors: quality 32/100, value 52/100, growth 0/100. Its strongest factor is value.
MEDCL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $897.28M
- Revenue (TTM)
- $27.99M
- P/E
- —
- EPS
- -0.94
- Dividend yield
- —
- Beta (5Y)
- 0.92
- 52-week high
- €39.68
- 52-week low
- €19.69
- Avg volume (3M)
- —
- Shares outstanding
- 35.91M
- Employees
- 141
- Next earnings
- —
About MedinCell S.A.
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
- ISIN
- FR0004065605
- Founded
- 2003
- Listed since
- Oct 8, 2018
- Exchange
- Euronext Paris
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ZhuZhou QianJin Pharmaceutical Co.,LtdSHSE: 600479 | $909.90M | CN¥12.40 | +6.71% |
| Kaken Pharmaceutical Co., Ltd.TSE: 4521 | $906.36M | ¥3,775.00 | -4.79% |
| PT Soho Global Health TbkIDX: SOHO | $904.16M | Rp1,275.00 | -7.94% |
| Procter & Gamble Health LimitedBSE: 500126 | $897.79M | Rs5,232.00 | -1.32% |
| Hainan Haiyao Co., Ltd.SZSE: 000566 | $893.56M | CN¥4.62 | -1.49% |
| Sanofi Consumer Healthcare India LimitedNSEI: SANOFICONR | $886.34M | Rs3,722.90 | -0.36% |
| Mega Lifesciences Public Company LimitedSET: MEGA | $876.44M | ฿33.75 | -2.88% |
| Alumis Inc.NasdaqGS: ALMS | $876.28M | $6.97 | +2.95% |
Figures last refreshed Oct 4, 2026.